P/E ratio for ANI Pharmaceuticals (ANIP)

P/E ratio history for ANI Pharmaceuticals from 2001 to 2026

PE ratio at the end of each year

P/E ratio for similar companies or competitors

Company	P/E ratio	P/E ratio differencediff.	Country
Novartis NVS	22.3	21.17%	🇨🇭 Switzerland
Pfizer PFE	20.6	12.02%	🇺🇸 USA
Cardinal Health CAH	36.1	95.85%	🇺🇸 USA
Jazz Pharmaceuticals JAZZ	558	2,925.28%	🇮🇪 Ireland
Evoke Pharma EVOK	-4.37	-123.68%	🇺🇸 USA
Celldex Therapeutics CLDX	-10.1	-154.72%	🇺🇸 USA
Teva Pharmaceutical Industries TEVA	26.4	43.11%	🇮🇱 Israel
Royalty Pharma RPRX	30.4	65.10%	🇬🇧 UK
Lannett Company LCI	-0.0271	-100.15%	🇺🇸 USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.